1,72 €
0,24 % gestern
L&S, 7. Oktober, 22:54 Uhr
ISIN
US67577R1023
Symbol
IRD
Berichte

Ocuphire Pharma Inc Aktie News

Neutral
GlobeNewsWire
6 Tage alt
RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it will present the positive clinical results from both its IRD gene therapy and Phentolamin...
Neutral
Seeking Alpha
7 Tage alt
Opus Genetics, Inc. - Special Call Company Participants Jenny Kobin George Magrath - CEO & Director Sally Tucker Conference Call Participants Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Gum-Ming Lowe - Craig-Hallum Capital Group LLC, Research Division Dev Prasad - Lucid Capital Markets, LLC, Research Division Matthew Caufield - H.C. Wainwright & Co, LLC, R...
Neutral
GlobeNewsWire
8 Tage alt
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicities Lasting, durable responses observed out to 18 months in adult participants Expected FDA Meeting in Q4 2025 Management to Host Webcast and Conference Call Today at 8:30 A.M. ET RESEARCH TRIANGLE PARK, N.C.
Neutral
GlobeNewsWire
26 Tage alt
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards...
Neutral
GlobeNewsWire
etwa ein Monat alt
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, today announced that the first patient has been dosed in LYNX-3, the Company's pivotal Phase 3 clinical trial evaluating Phentola...
Neutral
GlobeNewsWire
etwa ein Monat alt
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that George Magrath, MD, Chief Executive Officer, and Ash Jay...
Neutral
GlobeNewsWire
etwa ein Monat alt
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc.
Neutral
GlobeNewsWire
etwa ein Monat alt
RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it will present on its IRD gene therapy programs at the following scientific conferences in S...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen